胃食道逆流症(GERD)治療薬・治療機器のアジア太平洋市場予測

調査会社Inkwood Research社が発行したリサーチレポート(データ管理コード:INK902173)
◆英語タイトル:ASIA PACIFIC GERD DRUGS AND DEVICES MARKET FORECAST 2019-2027
◆発行会社/調査会社:Inkwood Research
◆商品コード:INK902173
◆発行日:2018年11月
◆調査対象地域:アジア、日本、中国、インドなど
◆産業分野:HEALTHCARE, MEDICAL DEVICES
◆ページ数:85
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥140,000見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥168,000見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD2,000 ⇒換算¥224,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Inkwood Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[胃食道逆流症(GERD)治療薬・治療機器のアジア太平洋市場予測]についてメールでお問い合わせはこちら
Inkwoodリサーチが調査・発行した本調査レポートでは、胃食道逆流症(GERD)治療薬・治療機器のアジア太平洋(アジア、日本、中国、インドなど)市場について調べ、胃食道逆流症(GERD)治療薬・治療機器の市場動向、市場規模、セグメント別胃食道逆流症(GERD)治療薬・治療機器の市場規模、主要企業情報などをまとめました。
*** レポート概要(サマリー)***

KEY FINDINGSThe APAC region market for GERD drugs and devices account growth of 1.52% CAGR through the forecasted years of 2019-2027. This region includes Japan, China, India, South Korea, Australia and the Rest of Asia.
MARKET INSIGHTS
The largest revenue contributor to the APAC market for GERD drugs and devices are Japan, China and India because of driving factors like availability of fewer approved drugs to treat GERD and increasing awareness about GERD among the patients that are pushing the growth of this market.
COMPETITIVE INSIGHTS
Some of the companies that provides additional revenue of the global GERG drugs and devices market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.

*** レポート目次(コンテンツ)***

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ANTACIDS DRUG CLASS HOLDS THE LARGEST MARKET SHARE
3.2.2. BRAVO SYSTEM DEVICES ARE WIDELY USED
4. MARKET DYNAMICS
4.1. MARKET SCOPE & DEFINITION
4.2. MARKET DRIVERS
4.2.1. GROWING TREND OF SELF-MEDICATION
4.2.2. INCREASING AWARENESS ABOUT GERD
4.2.3. INCREASING OCCURRENCE OF GERD DISORDERS
4.2.4. CHANGES IN LIFESTYLE
4.3. MARKET RESTRAINTS
4.3.1. PATENT EXPIRY
4.3.2. ADVERSE EFFECT OF PROTON PUMP INHIBITORS AND OTHER DRUGS
4.3.3. PROTON PUMP INHIBITOR RESISTANCE
4.4. MARKET OPPORTUNITIES
4.4.1. INCREASED PRACTICE OF GENERICS AND OTC DRUGS
4.4.2. COST-EFFECTIVE OTC DRUGS
4.4.3. OVERUSE OF MEDICATION AND DIETARY SUPPLEMENTS
4.5. MARKET CHALLENGES
4.5.1. USE OF COMPLEMENTARY AND ALTERNATIVE TREATMENTS
4.5.2. PROBABILITY OF BUYING COUNTERFEIT DRUGS
4.6. MARKET BY DRUGS DOSAGE FORM
4.7. MARKET BY ROUTE OF ADMINISTRATION OF DRUGS
5. MARKET BY DRUGS AND DEVICES
5.1. DRUG CLASS
5.1.1. ANTACIDS
5.1.2. H2 RECEPTOR BLOCKERS
5.1.3. PROTON PUMP INHIBITORS (PPI)
5.1.4. PRO-KINETIC AGENTS
5.2. DEVICES
5.2.1. DIGITRAPPER
5.2.2. BRAVO SYSTEM
5.2.3. STRETTA
5.2.4. LINX REFLUX MANAGEMENT SYSTEM
5.2.5. MUSE (MEDIGUS ULTRASONIC SURGICAL ENDOSTAPLER) SYSTEM
5.2.6. OTHER DEVICES
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE
6.1.3. BARGAINING POWER OF SUPPLIERS
6.1.4. BARGAINING POWER OF BUYERS
6.1.5. THREAT OF COMPETITIVE RIVALRY
6.2. PIPELINE DRUGS
6.3. REGULATORY FRAMEWORK
6.4. PATENT ANALYSIS
6.5. OPPORTUNITY MATRIX
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC
7.1.1. JAPAN
7.1.2. CHINA
7.1.3. INDIA
7.1.4. AUSTRALIA
7.1.5. SOUTH KOREA
7.1.6. REST OF ASIA PACIFIC
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. COMPANY PROFILES
8.2.1. ABBOTT LABORATORIES.
8.2.1.1. COMPANY OVERVIEW
8.2.1.2. PRODUCT PORTFOLIO
8.2.1.3. SCOT ANALYSIS
8.2.1.4. STRATEGIC INITIATIVES
8.2.2. ASTRAZENECA
8.2.2.1. COMPANY OVERVIEW
8.2.2.2. PRODUCT PORTFOLIO
8.2.2.3. SCOT ANALYSIS
8.2.2.4. STRATEGIC INITIATIVES
8.2.3. BAUSCH HEALTH (FORMERLY VALEANT PHARMACEUTICALS INTERNATIONAL, INC.)
8.2.3.1. COMPANY OVERVIEW
8.2.3.2. PRODUCT PORTFOLIO
8.2.3.3. SCOT ANALYSIS
8.2.3.4. STRATEGIC INITIATIVES
8.2.4. BOSTON SCIENTIFIC CORPORATION
8.2.4.1. COMPANY OVERVIEW
8.2.4.2. PRODUCT PORTFOLIO
8.2.4.3. SCOT ANALYSIS
8.2.4.4. STRATEGIC INITIATIVES
8.2.5. CEMPRA INC. (MERGED WITH MELINTA)
8.2.5.1. COMPANY OVERVIEW
8.2.5.2. PRODUCT PORTFOLIO
8.2.5.3. SCOT ANALYSIS
8.2.5.4. STRATEGIC INITIATIVES
8.2.6. DAEWOONG CO. LTD.
8.2.6.1. COMPANY PROFILES
8.2.6.2. PRODUCT PORTFOLIO
8.2.6.3. STRATEGIC INITIATIVES
8.2.7. EISAI INC
8.2.7.1. COMPANY OVERVIEW
8.2.7.2. PRODUCT PORTFOLIO
8.2.7.3. SCOT ANALYSIS
8.2.7.4. STRATEGIC INITIATIVES
8.2.8. GLAXOSMITHKLINE
8.2.8.1. COMPANY OVERVIEW
8.2.8.2. PRODUCT PORTFOLIO
8.2.8.3. SCOT ANALYSIS
8.2.8.4. STRATEGIC INITIATIVES
8.2.9. IRONWOOD PHARMACEUTICALS, INC.
8.2.9.1. COMPANY OVERVIEW
8.2.9.2. PRODUCT PORTFOLIO
8.2.9.3. SCOT ANALYSIS
8.2.9.4. STRATEGIC INITIATIVES
8.2.10. JOHNSON & JOHNSON
8.2.10.1. COMPANY OVERVIEW
8.2.10.2. PRODUCT PORTFOLIO
8.2.10.3. SCOT ANALYSIS
8.2.10.4. STRATEGIC INITIATIVES
8.2.11. MERCK & CO., INC.
8.2.11.1. COMPANY PROFILES
8.2.11.2. PRODUCT PORTFOLIO
8.2.11.3. SCOT ANALYSIS
8.2.11.4. STRATEGIC INITIATIVES
8.2.12. NOVARTIS
8.2.12.1. COMPANY OVERVIEW
8.2.12.2. PRODUCT PORTFOLIO
8.2.12.3. SCOT ANALYSIS
8.2.12.4. STRATEGIC INITIATIVES
8.2.13. PFIZER, INC.
8.2.13.1. COMPANY PROFILES
8.2.13.2. PRODUCT PORTFOLIO
8.2.13.3. SCOT ANALYSIS
8.2.13.4. STRATEGIC INITIATIVES
8.2.14. RAQUAL IA PHARMA INC.
8.2.14.1. COMPANY OVERVIEW
8.2.14.2. PRODUCT PORTFOLIO
8.2.14.3. STRATEGIC INITIATIVES
8.2.15. TAKEDA PHARMACEUTICALS COMPANY LIMITED
8.2.15.1. COMPANY OVERVIEW
8.2.15.2. PRODUCT PORTFOLIO
8.2.15.3. SCOT ANALYSIS
8.2.15.4. STRATEGIC INITIATIVES

LIST OF TABLES
TABLE 1 ASIA PACIFIC GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
TABLE 2 ASIA PACIFIC GERD DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2019-2027 ($ MILLION)
TABLE 3 ASIA PACIFIC DRUG CLASS MARKET BY TYPES 2019-2027 ($ MILLION)
TABLE 4 ASIA PACIFIC DRUG CLASS MARKET 2019-2027 ($ MILLION)
TABLE 5 ASIA PACIFIC ANTACIDS MARKET 2019-2027 ($ MILLION)
TABLE 6 ASIA PACIFIC H2 RECEPTOR BLOCKERS MARKET 2019-2027 ($ MILLION)
TABLE 7 ASIA PACIFIC H2 RECEPTOR BLOCKERS MARKET BY TYPES 2019-2027 ($ MILLION)
TABLE 8 ASIA PACIFIC PROTON PUMP INHIBITORS (PPI) MARKET 2019-2027 ($ MILLION)
TABLE 9 ASIA PACIFIC PROTON PUMP INHIBITORS (PPI) MARKET BY TYPES 2019-2027 ($ MILLION)
TABLE 10 ASIA PACIFIC PRO-KINETIC AGENTS MARKET 2019-2027 ($ MILLION)
TABLE 11 ASIA PACIFIC DEVICES MARKET BY TYPES 2019-2027 ($ MILLION)
TABLE 12 ASIA PACIFIC DEVICES MARKET 2019-2027 ($ MILLION)
TABLE 13 ASIA PACIFIC DIGITRAPPER MARKET 2019-2027 ($ MILLION)
TABLE 14 ASIA PACIFIC BRAVO SYSTEM MARKET 2019-2027 ($ MILLION)
TABLE 15 ASIA PACIFIC STRETTA (MEDERITHERAPEUTICS) MARKET 2019-2027 ($ MILLION)
TABLE 16 ASIA PACIFIC LINX® REFLUX MANAGEMENT SYSTEM (TORAX MEDICAL) MARKET 2019-2027 ($ MILLION)
TABLE 17 ASIA PACIFIC MUSE™ (MEDIGUS ULTRASONIC SURGICAL ENDOSTAPLER) SYSTEM MARKET 2019-2027 ($ MILLION)
TABLE 18 ASIA PACIFIC OTHER DEVICES MARKET 2019-2027 ($ MILLION)
TABLE 19 ASIA PACIFIC GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
TABLE 20 ASIA PACIFIC GERD DRUGS AND DEVICES MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES
FIGURE 1 ASIA PACIFIC GERD DRUGS AND DEVICES MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)
FIGURE 2 ASIA PACIFIC GERD DRUGS AND DEVICES MARKET SHARE BY DRUGS AND DEVICES 2017 & 2027 (%)
FIGURE 3 PORTER’S FIVE FORCE MODEL
FIGURE 4 ASIA PACIFIC GERD DRUGS AND DEVICES MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
FIGURE 5 JAPAN GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
FIGURE 6 CHINA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
FIGURE 7 INDIA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
FIGURE 8 AUSTRALIA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
FIGURE 9 SOUTH KOREA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
FIGURE 10 REST OF ASIA PACIFIC GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)
FIGURE 11 GERD PPIS DRUGS PROVIDER COMPANY MARKET SHARE 2017 (%)



*** レポートのキーワード ***

胃食道逆流症(GERD)治療薬・治療機器

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(INK902173 )"胃食道逆流症(GERD)治療薬・治療機器のアジア太平洋市場予測" (英文:ASIA PACIFIC GERD DRUGS AND DEVICES MARKET FORECAST 2019-2027)はInkwood Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。